As many have pointed out, the control arm is no longer SOC and this just adds to numerous ‘me too‘ regimens in frontline non driver mutation NSCLC- atezolizumab, nivo/ipi alone to name a few. It will not greatly impact current practice. If this leads to a price war and brings down the co...

The CheckMate 9LA study showed that combination of chemotherapy + Nivo/Ipi resulted in a survival benefit compared to chemotherapy alone, much like the other key immunotherapy trials in the NSCLC space, (e.g. KEYNOTE-189, IMpower150, POSEIDON). Cross-trial comparisons are di...

While I still consider chemotherapy plus pembrolizumab as the best choice (weighing efficacy and toxicity) for most patients with PD-L1 0% or 1-49% driver mutation negative mNSCLC, I have treated 2-3 patients with 9LA, in general, the initial toxicity is higher during the chemo-ipi-nivo phase, howev...

The CheckMate 9LA regimen with ipilimumab and nivolumab with 2 cycles of chemotherapy is a potential choice for front line therapy in a patient who would like to limit chemotherapy. The 2 year survival analysis presented at ASCO demonstrates continued survival benefit over chemotherapy alone. When t...